Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Inclusion Criteria: * At least 6 years of age. * Documented diagnosis of sickle cell disease. * Diagnosis of vaso-occlusive crisis necessitating admission to the hospital with treatment including IV opioids. * Able to receive the first dose of study drug within 24 hours from the administration of IV opioids. Exclusion Criteria: * Serious systemic infection * Acute Chest Syndrome * Serious concomitant medical problems (for example, stroke) * SCD pain atypical of VOC * Severe renal or hepatic impairment * Chronic pain rather than a presentation of acute VOC